158 related articles for article (PubMed ID: 37532976)
1. Development and characterization of fused human arginase I for cancer therapy.
Jawalekar SS; Kawathe PS; Sharma N; Anakha J; Tikoo K; Pande AH
Invest New Drugs; 2023 Oct; 41(5):652-663. PubMed ID: 37532976
[TBL] [Abstract][Full Text] [Related]
2. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis.
Lam TL; Wong GK; Chow HY; Chong HC; Chow TL; Kwok SY; Cheng PN; Wheatley DN; Lo WH; Leung YC
Pigment Cell Melanoma Res; 2011 Apr; 24(2):366-76. PubMed ID: 21029397
[TBL] [Abstract][Full Text] [Related]
5. Deprivation of arginine by recombinant human arginase in prostate cancer cells.
Hsueh EC; Knebel SM; Lo WH; Leung YC; Cheng PN; Hsueh CT
J Hematol Oncol; 2012 Apr; 5():17. PubMed ID: 22546217
[TBL] [Abstract][Full Text] [Related]
6. Human arginase I: a potential broad-spectrum anti-cancer agent.
Anakha J; Prasad YR; Sharma N; Pande AH
3 Biotech; 2023 May; 13(5):159. PubMed ID: 37152001
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells.
Zeng X; Li Y; Fan J; Zhao H; Xian Z; Sun Y; Wang Z; Wang S; Zhang G; Ju D
Cell Death Dis; 2013 Oct; 4(10):e840. PubMed ID: 24113174
[TBL] [Abstract][Full Text] [Related]
8. Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment.
Yu KM; Pang TP; Cutler M; Tian M; Huang L; Lau JY; Chung SF; Lo TW; Leung TY
Life Sci; 2021 Jan; 264():118674. PubMed ID: 33129876
[TBL] [Abstract][Full Text] [Related]
9. Blocking autophagy enhanced leukemia cell death induced by recombinant human arginase.
Li Y; Zeng X; Wang S; Fan J; Wang Z; Song P; Mei X; Ju D
Tumour Biol; 2016 May; 37(5):6627-35. PubMed ID: 26643895
[TBL] [Abstract][Full Text] [Related]
10. A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor.
Shen W; Zhang X; Fu X; Fan J; Luan J; Cao Z; Yang P; Xu Z; Ju D
Cell Death Dis; 2017 Mar; 8(3):e2720. PubMed ID: 28358368
[TBL] [Abstract][Full Text] [Related]
11. Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
Cheng PNM; Liu AM; Bessudo A; Mussai F
Invest New Drugs; 2021 Dec; 39(6):1633-1640. PubMed ID: 34287772
[TBL] [Abstract][Full Text] [Related]
12. The role of autophagy in the cytotoxicity induced by recombinant human arginase in laryngeal squamous cell carcinoma.
Lin C; Wang Z; Li L; He Y; Fan J; Liu Z; Zhao S; Ju D
Appl Microbiol Biotechnol; 2015 Oct; 99(20):8487-94. PubMed ID: 25904129
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human arginase I elicited immunosuppression in activated macrophages through inhibiting autophagy.
Wang Z; Song P; Li Y; Wang S; Fan J; Zhang X; Luan J; Chen W; Wang Y; Liu P; Ju D
Appl Microbiol Biotechnol; 2019 Jun; 103(12):4825-4838. PubMed ID: 31053913
[TBL] [Abstract][Full Text] [Related]
14. Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells.
Wang Z; Shi X; Li Y; Zeng X; Fan J; Sun Y; Xian Z; Zhang G; Wang S; Hu H; Ju D
Appl Microbiol Biotechnol; 2014 Mar; 98(6):2485-94. PubMed ID: 23917632
[TBL] [Abstract][Full Text] [Related]
15. Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells.
Wang Z; Shi X; Li Y; Fan J; Zeng X; Xian Z; Wang Z; Sun Y; Wang S; Song P; Zhao S; Hu H; Ju D
Cell Death Dis; 2014 Dec; 5(12):e1563. PubMed ID: 25501824
[TBL] [Abstract][Full Text] [Related]
16. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.
Stone E; Chantranupong L; Gonzalez C; O'Neal J; Rani M; VanDenBerg C; Georgiou G
J Control Release; 2012 Feb; 158(1):171-9. PubMed ID: 22001609
[TBL] [Abstract][Full Text] [Related]
17. Pegylated Recombinant Human Arginase 1 Induces Autophagy and Apoptosis via the ROS-Activated AKT/mTOR Pathway in Bladder Cancer Cells.
Zhao Z; Zhang P; Li W; Wang D; Ke C; Liu Y; Ho JC; Cheng PN; Xu S
Oxid Med Cell Longev; 2021; 2021():5510663. PubMed ID: 33791071
[TBL] [Abstract][Full Text] [Related]
18. Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.
De Santo C; Cheng P; Beggs A; Egan S; Bessudo A; Mussai F
J Hematol Oncol; 2018 May; 11(1):68. PubMed ID: 29776373
[TBL] [Abstract][Full Text] [Related]
19. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.
Yau T; Cheng PN; Chan P; Chen L; Yuen J; Pang R; Fan ST; Wheatley DN; Poon RT
Invest New Drugs; 2015 Apr; 33(2):496-504. PubMed ID: 25666409
[TBL] [Abstract][Full Text] [Related]
20. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
Chan SL; Cheng PNM; Liu AM; Chan LL; Li L; Chu CM; Chong CCN; Lau YM; Yeo W; Ng KKC; Yu SCH; Mok TSK; Chan AWH
Invest New Drugs; 2021 Oct; 39(5):1375-1382. PubMed ID: 33856599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
